

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-27 (Cancelled).

Claim 28 (Currently Amended): An immunogen derived from Bet v 1 protein allergen, comprising

a) a non-anaphylactic immunogenic recombinant fragment of the protein allergen, said fragment comprising an IgG epitope and an IgE epitope of the protein allergen partly but not completely overlapping;

b) a polymeric form of said fragment, in which form the fragment constitutes the monomeric units, wherein said monomeric units are separated from each other by an oligopeptide linker; or

c) a non-anaphylactic recombinant polymeric form of said protein allergen ~~having~~ consisting of 2 to 10 monomeric units in which the protein allergen constitutes the monomeric units, wherein said monomeric units are separated from each other by an oligopeptide linker.

Claim 29 (Cancelled).

Claim 30 (Previously Presented): The immunogen of claim 28, wherein said immunogen is according to (b) or (c) and said oligopeptide linker comprises 1-30 amino acid residues.

Claim 31 (Previously Presented): The immunogen of claim 30, wherein said amino acid residues are hydrophilic.

Claim 32 (Previously Presented): An immunogen derived from Bet v 1 protein allergen, comprising a non-anaphylactic immunogenic recombinant fragment of the protein allergen, said fragment comprising an IgG epitope and an IgE epitope of the protein allergen partly but not completely overlapping, wherein the fragment comprises SEQ ID NO:19.

Claim 33 (Previously Presented): An immunogen derived from Bet v 1 protein allergen, comprising a non-anaphylactic immunogenic recombinant fragment of the protein allergen, said fragment comprising an IgG epitope and an IgE epitope of the protein allergen partly but not completely overlapping, wherein the fragment comprises SEQ ID NO:20.

Claim 34 (Previously Presented): An immunogen derived from Bet v 1 protein allergen, comprising a non-anaphylactic immunogenic recombinant fragment of the protein allergen, said fragment comprising an IgG epitope and an IgE epitope of the protein allergen partly but not completely overlapping, wherein the fragment comprises SEQ ID NO:21.

Claim 35 (Previously Presented): The immunogen of claim 28, comprising a non-anaphylactic immunogenic recombinant fragment of the protein allergen, said fragment comprising an IgG epitope and an IgE epitope of the protein allergen partly but not completely overlapping.

Claim 36 (Currently Amended): An immunogen derived from Bet v 1 protein allergen, comprising

~~a) a non-anaphylactic immunogenic recombinant fragment of the protein allergen, said fragment comprising an IgG epitope and an IgE epitope of the protein allergen partly but not completely overlapping;~~

~~b) a polymeric form of said fragment~~ a non-anaphylactic immunogenic recombinant fragment of the protein allergen, said fragment comprising an IgG epitope and an IgE epitope of the protein allergen partly but not completely overlapping, in which form the fragment constitutes the monomeric units, wherein said monomeric units are separated from each other by an oligopeptide linker and; ~~or~~

~~c) a non-anaphylactic recombinant polymeric form of said protein allergen having 2 to 10 monomeric units in which the protein allergen constitutes the monomeric units, wherein said monomeric units are separated from each other by an oligopeptide linker,~~

wherein the polymeric form of said fragment is recombinantly produced.